ZBIOHIGH SIGNALOPPORTUNITY10-K

ZBIO reported positive Phase 3 results for obexelimab in IgG4-RD showing 56% reduction in disease flare risk, positioning the company to file for FDA approval.

The successful Phase 3 INDIGO trial represents a major clinical milestone that could transform ZBIO from a development-stage company into a commercial entity if FDA approval is granted. The statistically significant results across primary and secondary endpoints, combined with a favorable safety profile, substantially de-risk the regulatory pathway and validate the company's lead asset.

Comparing 2026-03-16 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company in intensive late-stage development with cash burn accelerating significantly - net losses increased 141% to $377.7M while operating cash outflows rose 44% to $172.3M, and R&D spending grew 21% to $168.1M. Cash reserves declined 65% to $110.6M while total liabilities more than doubled to $141.5M, indicating substantial funding needs despite doubling revenue to $10M. This cash trajectory suggests the company will need additional financing to support commercialization efforts following the positive Phase 3 results.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+146%
$57.5M→$141.5M

Liabilities grew 146% — significant increase in debt or obligations, assess impact on financial flexibility.

Net Income
P&L
-140.6%
-$157.0M→-$377.7M

Net income declined 140.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-133.7%
-$163.9M→-$383.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+100%
$5.0M→$10.0M

Strong top-line growth of 100% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
-86.3%
$131K→$18K

Capex reduced 86.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-65.4%
$319.7M→$110.6M

Cash declined 65.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-44%
-$119.7M→-$172.3M

Operating cash flow fell 44% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
-22.5%
$312.5M→$242.1M

Equity decreased 22.5% — buybacks or losses reducing book value, monitor solvency ratios.

R&D Expense
P&L
+20.8%
$139.1M→$168.1M

R&D investment increased 20.8% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-11
ADDED
Our lead I I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc RIIb, which are broadly present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
The first three indications we are pursuing include immunoglobulin G4-related disease ( IgG4-RD ) through a registration-directed Phase 3 trial which reported topline data in January 2026, and relapsing multiple sclerosis ( RMS ), through a Phase 2, double-blind, randomized, placebo-controlled trial which reported topline data in October 2025, and systemic lupus erythematosus ( SLE ) through an ongoing Phase 2, double-blind, randomized, placebo-controlled trial for which we expect to report topline results, including biomarker data, in the fourth quarter of 2026.
In January 2026, we reported positive results from the Phase 3 trial of obexelimab in patients with IgG4-RD (the INDIGO ) trial.
Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo (Hazard Ratio 0.44, p=0.0005) and also met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints.
Obexelimab was well tolerated with a safety profile consistent with that observed in previously completed clinical trials.
+7 more — sign up free →
REMOVED
With the evolving understanding of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an immunology and inflammation ( I I ) focused biopharmaceutical company.
The first three indications we are pursuing include immunoglobulin G4-related disease ( IgG4-RD ) through an ongoing registration-directed Phase 3 trial which completed enrollment in November 2024 and relapsing multiple sclerosis ( RMS ) and systemic lupus erythematosus ( SLE ) through ongoing Phase 2, double-blind, randomized, placebo-controlled trials, each of which are currently enrolling.
Beyond our lead product candidate, obexelimab, we have two other programs for the potential treatment of other I I indications that we may continue to advance and ultimately develop and commercialize with partners.
Other anti-CD19 and CD20 targeting antibodies rely on antibody-dependent cell-mediated cytotoxicity ( ADCC ), complement-dependent cytotoxicity ( CDC ) and/or apoptosis or programmed cell death as a key component of their mechanism of action.
Obexelimab has been evaluated in five completed clinical trials in which a total of 198 subjects have received obexelimab either as IV infusion at doses of up to 10 mg/kg (n=158) or as a SC injection at doses of up to 375 mg (n=40).
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →